The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Mural Oncology a clinical-stage oncology company focused on discovering and developing immunotherapies, held its first ...

Perioperative pembrolizumab can improve OS when combined with neoadjuvant chemotherapy in patients with high risk, ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

A huge leap in fine for wrongly using mobility parks, help with childcare costs and access to Keytruda are just some of the ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...